新的β受体阻滞剂在高血压中的应用  

Application of New Beta-blockers in Hypertension

作　　者：史珂[1] 韩常宝[1] 

机构地区：[1]北京军区总医院263临床部心肾内科,北京101149

出　　处：《医学综述》2011年第20期3132-3135,共4页Medical Recapitulate

摘　　要：β受体阻滞剂用于治疗高血压病已有几十年的历史,新的β受体阻滞剂在高血压病治疗中仍然具有一定的优势。拉贝洛尔是一种具有α1受体阻滞活性的非选择性β受体阻滞剂,临床上主要用于降低舒张压;卡维地洛是一种不具备内交感活性的非选择性β受体阻滞剂,用于高血压、心力衰竭、心肌梗死后左心功能不全的治疗;奈必洛尔是一种具有高度选择性的β1受体阻滞剂,对于高血压合并糖尿病患者,奈必洛尔表现出良好的降压作用。β blockers have been used in treatment of hypertension for decades,new β blockers have some advantages in the treatment of hypertension.Labetalol is a nonselective β blocker with α1 receptor-blocking activity,it is more effective in lowering DBP;carvedilol is a nonselective β blocker with no intrinsic sympathomimetic activity,which is indicated for use in patients with hypertension,heart failure and post-myocardial infarction left ventricular dysfunction;Nebivolol is a high β1-selective β blocker,which significantly lowers blood pressure in patients with hypertension and diabetes.

关 键 词：Β受体阻滞剂 拉贝洛尔 卡维地洛 奈必洛尔 

分 类 号：R541.3[医药卫生—心血管疾病]